Phospholipid derived mediators and glomerulonephritis

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The contributions made by the various eicosanoids, PAF, the HETES and the lipoxins to the pathophysiology of glomerulonephritis is reviewed. A case can be made for clinical trials of PAF, leukotriene and thromboxane antagonists. Combined thromboxane synthetase and thromboxane receptor antagonism would seem to be the more efficacious approach for the various disease entities.

